FDA 483 - Philip NMI Raskin - January 11, 2024

An FDA inspection of Philip NMI Raskin, MD, Clinical Investigator in Dallas, TX, revealed that an investigation was not conducted in accordance with the investigational plan. Specifically, the study drug was not suspended for subjects experiencing adverse events as required by the protocol. This indicates a significant deviation from established study procedures.